论文部分内容阅读
目的探讨吡格列酮和二甲双胍治疗对肥胖T2DM患者血清APN的不同影响。方法将48例新诊断的肥胖T2DM患者随机分两组,分别给予二甲双胍(M组)和二甲双胍联合吡格列酮(MP组)治疗12周;于治疗前后测定受试者空腹血清APN、FPG、HbA1c、血脂、FIns,计算BMI、胰岛素抵抗指数(HOMA-IR)。结果与治疗前相比,MP组APN水平明显升高(P=0.0005),MP组FPG、HbA1c、HOMA-IR、BMI、FIns明显降低(P<0.05);与治疗前相比,M组APN水平无明显改变(P=0.487),BMI、FPG、HbA1c、HOMA-IR、FIns、LDL-C明显降低(P<0.05)。结论吡格列酮能有效增加肥胖T2DM患者血清APN水平。
Objective To investigate the different effects of pioglitazone and metformin on serum APN in obese T2DM patients. Methods Forty-eight newly diagnosed obese T2DM patients were randomly divided into two groups and were given metformin (M group) and metformin combined with pioglitazone (MP group) for 12 weeks respectively. Before and after treatment, fasting serum APN, FPG, HbA1c, , FIns, calculated BMI, insulin resistance index (HOMA-IR). Results The levels of APN in MP group were significantly higher than those before treatment (P = 0.0005). The levels of FPG, HbA1c, HOMA-IR, BMI and FIns in MP group were significantly lower than those before treatment (P = 0.487). The levels of BMI, FPG, HbA1c, HOMA-IR, FIns and LDL-C were significantly lower than those before treatment (P <0.05). Conclusion Pioglitazone can effectively increase serum APN levels in obese T2DM patients.